Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients

Ishikawa, Toru

doi:10.3748/wjg.14.6140

Cited by 27 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, 2 reviews [19,20] and 6 meta-analyses [21,22,23,24,25,26] were published regarding the recurrence-preventing or survival-prolonging effect of IFN therapy after the resection or ablation of HCC. All of them suggested that IFN is effective in preventing recurrence or improving survival.…”

Section: Meta-analyses Of the Recurrence-preventing Or Survival-prolomentioning

confidence: 99%

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Kudo

2011

Oncology

View full text Add to dashboard Cite

It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15–20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80–90%. This recurrence rate is also known to be similar after various curative treatments including resection, percutaneous ethanol injection therapy, and radiofrequency ablation. Generally, in treating patients with HCC associated with hepatitis C or liver cirrhosis, aggressive efforts to prevent secondary carcinogenesis are necessary rather than simply observing the clinical course after treatment. Presently, a combination of peg-interferon and ribavirin is known to be highly effective in patients with difficult-to-treat hepatitis C with a high viral load and genotype I virus. Therefore, indications of these treatments must be considered to prevent secondary carcinogenesis in patients with hepatitis C. Recently, long-term follow-up of low-dose, long-term maintenance therapy using pegylated interferon-α2a for cirrhotic patients clearly showed a preventive effect on HCC occurrence and recurrence. Preventing secondary carcinogenesis by suppressing inflammation employing the same treatment as that against primary carcinogenesis is also important. The molecular targeted agent sorafenib markedly suppresses the serine/threonine kinases of Raf in the MAP kinase cascade and inhibits the tyrosine kinases of angiogenesis factor receptors such as vascular endothelial growth factor and platelet-derived growth factor receptors. It thus simultaneously prevents the proliferation of tumors and inhibits angiogenesis. A clinical trial to examine the recurrence-preventing effect of sorafenib by administration of it after curative treatment such as resection or ablation is in progress (STORM trial: http://clinicaltrials.gov.com, NCT00692770). Treatments to prevent recurrence (including intrahepatic metastasis and multicentric carcinogenesis) as well as early detection and early curative treatment are extremely important to improve the prognosis of patients with HCC. Thus, further research on this issue should be carried out, especially in relation to molecular targeted therapy.

show abstract

Section: Meta-analyses Of the Recurrence-preventing Or Survival-prolomentioning

confidence: 99%

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Kudo

2011

Oncology

View full text Add to dashboard Cite

show abstract

“…Thus IFN-α therapy for hepatitis B (HBV) and C (HCV) viral infections suppresses carcinogenesis and improves liver function [49][50][51][52]. Moreover, IFN-α therapy eliminates HCV mRNA, and reduces the development of HCC in patients with normalized transaminase levels [53]. Additionally, although a complete antitumor response is not achieved, IFN-α therapy suppresses HCC when compared with untreated cases [49,52,54].…”

Section: Ifns In Clinical Oncologymentioning

confidence: 99%

IFN-λ Cancer Immunotherapy: New Kid on the Block

et al. 2016

View full text Add to dashboard Cite

Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.

show abstract

“…Thus, IFN-α therapy for HBV and HCV infections suppresses carcinogenesis and improves liver function [5, 6]. Moreover, IFN therapy eliminates HCV mRNA, and reduces the onset of HCC in patients with normalized transaminase levels [7]. Although IFN-α therapy suppressed HCC, complete tumor eradication is rarely obtained.…”

Section: Introductionmentioning

confidence: 99%

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth

Lasfar¹,

Torre

Abushahba

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-λ, a new type of IFN that acts through its own receptor complex. In the present study, the antitumor efficacy of the combination of IFN-α and IFN-λ was tested in the BNL mouse hepatoma model. This study was accomplished by using either engineered tumor cells (IFN-α/IFN-λ gene therapy) or by directly injecting tumor-bearing mice with IFN-α/IFN-λ. Both approaches demonstrated that IFN-α/IFN-λ combination therapy was more efficacious than IFN monotherapy based on either IFN-α or IFN-λ. In complement to tumor surgery, IFN-α/IFN-λ combination induced complete tumor remission. Highest antitumor efficacy has been obtained following local administration of IFN-α/IFN-λ combination at the tumor site that was associated with strong NK cells tumor infiltration. This supports the use of IFN-α/IFN-λ combination as a new cancer immunotherapy for stimulating antitumor response after cancer surgery.

show abstract

Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients

Cited by 27 publications

References 27 publications

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

IFN-λ Cancer Immunotherapy: New Kid on the Block

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth

Contact Info

Product

Resources

About